Adolor Corporation to Host Investor Conference Call To Report Third Quarter 2009 Financial Results

Business Wire

posted: 37 DAYS 22 HOURS AGO

Adolor Corporation (NasdaqGM: ADLR) today announced that it will hold a conference call at 8:45 a.m. ET on Thursday, October 29, 2009, to discuss third quarter 2009 financial results.

To participate in the audio portion and have the opportunity to pose questions, dial (866) 314-5232 for domestic callers or (617) 213-8052 for international callers, and enter Conference ID # 38530562. Investors also can listen to the call live by logging on to the Company’s website at www.adolor.com and clicking on “Investor Insights,” then "Calendar of Events."

A replay of the call will be available beginning approximately two hours after the event. To listen to a replay of the conference call, dial (888) 286-8010 (domestic) or (617) 801-6888 (international) and enter Conference ID # 83107323 or listen via Adolor’s website. The replay will be available for one week.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.™ Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. In collaboration with GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.

The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; two opioid receptor antagonists, ADL7445 and ADL 5945, entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.